TYK2 and sarcoma: Our laboratory utilized NGS and identified activating TYK2 mutations in malignant peripheral nerve sheath tumors (MPNST), an aggressive subtype of sarcomas associated with the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome [36].